A tribute to Dr. Gerald Burr Grindey, 1940–1993 Enrico MihichRichard G. MoranCharles A. Nichol Announcement Pages: 241 - 242
Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models R. L. MerrimanL. W. HertelG. B. Grindey OriginalPaper Pages: 243 - 247
Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside Robert L. Capizzi OriginalPaper Pages: 249 - 256
Gemcitabine and radiosensitization in human tumor cells Donna S. ShewachTheodore S. Lawrence OriginalPaper Pages: 257 - 263
Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine Daniel D. Von Hoffthe San Antonio Drug Development Team OriginalPaper Pages: 265 - 270
Antitumor diarylsulfonylureas: novel agents with unfulfilled promise Peter J. HoughtonJanet A. Houghton OriginalPaper Pages: 271 - 280
A simplified and efficient synthesis of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF) Edward C. TaylorRajendra ChaudhariKoo Lee OriginalPaper Pages: 281 - 285
Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol Laurane G. MendelsohnChuan ShihJohn F. Worzalla OriginalPaper Pages: 287 - 294
AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase Theodore J. BoritzkiCharlotte A. BarlettRobert C. Jackson OriginalPaper Pages: 295 - 303
TomudexTM (ZD1694): from concept to care, a programme in rational drug discovery Ann L. JackmanKenneth R. HarrapF. Thomas Boyle OriginalPaper Pages: 305 - 316
Exploitation of folate and antifolate polyglutamylation to achieve selective anticancer chemotherapy John J. McGuireTakashi TsukamotoJohn Galivan OriginalPaper Pages: 317 - 323
A Phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid Sudsawat LaohavinijStephen R. WedgeA. Hilary Calvert OriginalPaper Pages: 325 - 335
